Selective degradation of platelet BTK by PROTAC NX-5948 provides antithrombotic benefits without affecting hemostasis.
- DOI
- 10.1182/bloodadvances.2026019769
- Published
- 2026 Sep 22
- Container
- Blood advances
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1182/bloodadvances.2026019769,
title = {Selective degradation of platelet BTK by PROTAC NX-5948 provides antithrombotic benefits without affecting hemostasis.},
author = {May CJ and Trory JS and Webb CE and Walker HS and Li Y and Furniss JA and Eble JA and Poole AW and Vautrinot J and Tromans J and Hers I},
year = {2026},
journal = {Blood advances},
doi = {10.1182/bloodadvances.2026019769},
url = {https://doi.org/10.1182/bloodadvances.2026019769}
}RIS
TY - JOUR TI - Selective degradation of platelet BTK by PROTAC NX-5948 provides antithrombotic benefits without affecting hemostasis. AU - May CJ AU - Trory JS AU - Webb CE AU - Walker HS AU - Li Y AU - Furniss JA AU - Eble JA AU - Poole AW AU - Vautrinot J AU - Tromans J AU - Hers I PY - 2026 JO - Blood advances DO - 10.1182/bloodadvances.2026019769 UR - https://doi.org/10.1182/bloodadvances.2026019769 ER -
APA
CJ, M., JS, T., CE, W., HS, W., Y, L., JA, F., JA, E., AW, P., J, V., J, T., & I, H. (2026). Selective degradation of platelet BTK by PROTAC NX-5948 provides antithrombotic benefits without affecting hemostasis.. Blood advances. https://doi.org/10.1182/bloodadvances.2026019769
Source records
- pubmed · retrieved 2026-09-25T20:51:29.616Z